IPO-bound Intarcia hauls in $215M, and plans to add more; Peloton raises $52M round
With its highly touted diabetes drug/device ITCA 650 being set up for a promised launch late next year (if it’s approved), Intarcia has come up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
